Givastomig

DB18618InvestigationalProtein Based Therapies

Givastomig is an anti-Claudin 18.2 and 4.1BB bispecific antibody.

Mechanism: Pharmacologically active on Tumor necrosis factor receptor superfamily member 9 and Claudin-18
Curator reviewed
Also known as: an anti-Claudin 18.2 and 4.1BB Bispecific Antibody · TJ-CD4B/ABL111
Code names: ABL111 · TJ033721 · TJ-CD4B

Resolves to

Compound

Targets

What you can answer from here — as of July 09, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Givastomig, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.